Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N.

Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19.

PMID:
22262760
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3.

PMID:
23823317
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.

Clin Cancer Res. 2011 Aug 15;17(16):5311-21. doi: 10.1158/1078-0432.CCR-11-0476. Epub 2011 Jun 30.

PMID:
21724551
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.

PLoS One. 2012;7(12):e52576. doi: 10.1371/journal.pone.0052576. Epub 2012 Dec 20.

PMID:
23285100
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3773-81.

PMID:
16585204
[PubMed - indexed for MEDLINE]
Free Article
6.

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.

Eur J Haematol. 2010 Mar;84(3):201-11. doi: 10.1111/j.1600-0609.2009.01384.x. Epub 2009 Nov 18.

PMID:
19929977
[PubMed - indexed for MEDLINE]
7.
8.

Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN.

Clin Cancer Res. 2010 Oct 1;16(19):4742-54. doi: 10.1158/1078-0432.CCR-10-0529. Epub 2010 Jul 20.

PMID:
20647473
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC, Arnulf B.

Haematologica. 2012 Jul;97(7):1101-9. doi: 10.3324/haematol.2011.049981. Epub 2012 Jan 22.

PMID:
22271897
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
[PubMed - indexed for MEDLINE]
11.

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S.

Br J Haematol. 2007 Nov;139(3):385-97.

PMID:
17910628
[PubMed - indexed for MEDLINE]
12.

PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.

Kim J, Guan J, Chang I, Chen X, Han D, Wang CY.

Mol Cancer Ther. 2010 Jul;9(7):1977-84. doi: 10.1158/1535-7163.MCT-10-0141. Epub 2010 Jun 22.

PMID:
20571067
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC.

Blood. 2006 Nov 15;108(10):3441-9. Epub 2006 May 25.

PMID:
16728695
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ.

Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29.

PMID:
22932796
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.

Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz ES, Miranda E, Martín-Subero JI, Garate L, Blanco-Prieto MJ, García de Jalón JA, Rio P, Rifón J, Cigudosa JC, Martinez-Climent JA, Román-Gómez J, Calasanz MJ, Ribera JM, Prósper F.

Leukemia. 2012 Jul;26(7):1517-26. doi: 10.1038/leu.2012.31. Epub 2012 Feb 6.

PMID:
22307227
[PubMed - indexed for MEDLINE]
16.

Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.

Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK.

Mol Cancer Ther. 2013 May;12(5):747-58. doi: 10.1158/1535-7163.MCT-12-0811. Epub 2013 Mar 8.

PMID:
23475956
[PubMed - indexed for MEDLINE]
Free Article
17.

[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].

Zhang L, Ma YP, Jia G.

Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):926-31. Chinese.

PMID:
23363750
[PubMed - indexed for MEDLINE]
Free Article
18.

Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.

Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, Lomenick B, Okemoto K, Landaw EM, Wang D, Mazitschek R, Bradner JE, Sakamoto KM.

Leuk Lymphoma. 2011 Aug;52(8):1544-55. doi: 10.3109/10428194.2011.570821. Epub 2011 Jun 23.

PMID:
21699378
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.

Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y.

J Biol Chem. 2013 Aug 30;288(35):25593-602. doi: 10.1074/jbc.M113.480574. Epub 2013 Jul 22.

PMID:
23878197
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.

Blood. 2003 Nov 15;102(10):3765-74. Epub 2003 Jul 31.

PMID:
12893773
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk